Circulation:动脉粥样硬化患者消化道或泌尿道出血提示癌症

2019-11-02 QQY MedSci原创

采用抗血栓药物治疗的患者有出血的风险。出血可能是潜在癌症的第一表现。Eikelboom等人对COMPASS试验(采用抗凝药治疗的患者的心血管预后)患者胃肠道或泌尿生殖系统出血相与新诊断的癌症的相关性。COMPASS试验共纳入27395位患者(平均年龄68岁,女性占21%),其中2678位(8.9%)有出血表现(大出血或微出血),713位(2.6%)发生过大出血,1084位(4.0%)患者在平均随访

采用抗血栓药物治疗的患者有出血的风险。出血可能是潜在癌症的第一表现。

Eikelboom等人对COMPASS试验(采用抗凝药治疗的患者的心血管预后)患者肠道或泌尿生殖系统出血相与新诊断的癌症的相关性。

COMPASS试验共纳入27395位患者(平均年龄68岁,女性占21%),其中2678位(8.9%)有出血表现(大出血或微出血),713位(2.6%)发生过大出血,1084位(4.0%)患者在平均随访的23个月内确诊罹患癌症。对于2678位有出血表现的患者,257位(9.9%)随访过程中确诊癌症。肠道出血的患者确诊新发消化道癌症或非消化道癌症的风险分别是无胃肠道出血患者的20倍和1.7倍。泌尿生殖系统出血患者确诊泌尿生殖系统癌症的风险增加32倍,尿血与确诊新发尿道癌症的风险增加98倍相关。非消化道、非泌尿生殖道出血患者罹患非消化道、非泌尿生殖道癌症的风险增加3倍。

对于采用抗血栓药物治疗的动脉粥样硬化患者,无论是消化道出血还是泌尿生殖道出血均与新发癌症风险增加相关。因此,这类患者一旦出现消化道或泌尿道出血,应予以筛查癌症。

原始出处:

John W. Eikelboom, et al.Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.Circulation. 2019;140:1451–1459

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769155, encodeId=5e4c1e69155ef, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Tue Mar 24 01:35:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944629, encodeId=bc1d194462929, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Apr 20 23:35:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464633, encodeId=c93e146463367, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Mon Nov 04 14:35:00 CST 2019, time=2019-11-04, status=1, ipAttribution=)]
    2020-03-24 lifestar
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769155, encodeId=5e4c1e69155ef, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Tue Mar 24 01:35:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944629, encodeId=bc1d194462929, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Apr 20 23:35:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464633, encodeId=c93e146463367, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Mon Nov 04 14:35:00 CST 2019, time=2019-11-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1769155, encodeId=5e4c1e69155ef, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Tue Mar 24 01:35:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944629, encodeId=bc1d194462929, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Apr 20 23:35:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464633, encodeId=c93e146463367, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Mon Nov 04 14:35:00 CST 2019, time=2019-11-04, status=1, ipAttribution=)]

相关资讯

Circulation:载脂蛋白AI可促进动脉粥样硬化消退

虽然糖尿病患者的胆固醇水平显著降低,但其心血管疾病风险仍在增加。与此一致,糖尿病对人和小鼠胆固醇降低后的动脉粥样硬化消退过程有损害作用。在小鼠中,这在一定程度上归因于高血糖诱导的单核细胞增多症,增加了单核细胞进入斑块的机会,尽管胆固醇水平降低了。此外,糖尿病使斑块巨噬细胞向致动脉粥样硬化的炎性M1表型转化,而不是典型的伴有胆固醇降低的促动脉粥样硬化溶解的M2状态。在糖尿病患者中水平一般较低的功能性

Circulation:动脉粥样硬化患者出血与新发癌症的关系

由此可见,使用抗血栓药物治疗的动脉粥样硬化患者,任何胃肠道或泌尿生殖器出血都与新发癌症诊断相关。任何胃肠道或泌尿生殖系统出血都应该及时检查这些部位的癌症。

Stroke:ESUS 亚组,颈动脉粥样硬化抗凝还是抗血小板?

动脉粥样硬化性颈动脉病处于栓塞性卒中和其他严重不良心血管事件的风险之中。对于这组人群,改变生活方式和其他内科治疗措施比如他汀、抗血小板治疗是一级和二级预防的基石。

Curr Atheroscle Rep:从机制到实践,PCSK9抑制剂成为降脂治疗新选择

PCSK9是一种全新的低密度脂蛋白调节靶向物质,主要通过调节肝脏LDL受体(LDLR)的表达和分泌活性来发挥作用。现有研究已证实,个体PCSK9水平不仅是罕见的先天性LDL-C调控物质,更可以作为降低动脉粥样硬化性脂蛋白水平和心血管风险的新型药物靶点。Current Atherosclerosis Reports杂志近期发表了一项综述,汇总最新的相关临床研究成果,将其结论整合为临床亚组结论和新治疗